# Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency

> **NCT04138251** · PHASE2 · UNKNOWN · sponsor: **Cliniques universitaires Saint-Luc- Université Catholique de Louvain** · enrollment: 5 (estimated)

## Conditions studied

- Glycogen Storage Disease Type I
- Glucose 6 Phosphatase Deficiency

## Interventions

- **DRUG:** Empagliflozin

## Key facts

- **NCT ID:** NCT04138251
- **Lead sponsor:** Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-20
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2019-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04138251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04138251, "Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04138251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*